Hormonal
Postprandial lipemia, specifically the delayed clearance of triacylglycerol-rich lipoproteins (TRL) and their remnants, is a significant independent risk factor for the development and progression of atherosclerosis and coronary heart disease (CHD).
Cardiovascular risk isn't just about your fasting numbers. How your body processes fat after meals (postprandial lipemia) matters significantly for heart health. If you have a family history of heart disease, obesity, or insulin resistance, your body may clear fat from your blood more slowly after eating, which increases atherosclerosis risk. Focus on meal composition (fat type/amount) and lifestyle factors (exercise) to manage this response.
Several clinical studies have shown that a delayed elimination of postprandial TRL is associated with atherosclerosis... In The Montreal Heart Study... the concentration of hepatic TRL remnants predicted the progression of atherosclerosis.
Why this rating
The paper cites multiple clinical trials and mechanistic studies, but notes that standardization is lacking and causality is complex.
Source
Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism
José López‐Miranda et al. · British Journal Of Nutrition · 2007
DOI 10.1017/s000711450774268x
More from this paper
- Dietary fat type influences postprandial lipemia, with long-chain n-3 polyunsaturated fatty acids (PUFA) from fish oil significantly reducing postprandial triacylglycerol levels compared to saturated (SFA) or monounsaturated (MUFA) fats, provided sufficient doses (2.7-4 g/d) are consumed.Good
- Physical activity, particularly aerobic exercise performed before a meal, significantly reduces postprandial lipemia and increases lipoprotein lipase (LPL) activity, improving lipid clearance.Good
- Obesity, insulin resistance, and type 2 diabetes are pathological conditions associated with exaggerated and prolonged postprandial lipemia, characterized by delayed clearance of triacylglycerol-rich lipoproteins (TRL).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →